Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 66

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

IgA nephropathy

Not yet recruiting

Study on Corticosteroids, Dapagliflozin, and Drug Combination for Proteinuria in IgA Nephropathy Patients with Active or Chronic Kidney Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali

Haemophagocytic lymphohistiocytosis

Not yet recruiting

Gene Therapy Study for Familial Hemophagocytic Lymphohistiocytosis Using MUNC-CD34 and MUNC-T3 in Patients with UNC13D Gene Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Munc-Cd34
  • Sponsor:Assistance Publique Hopitaux De Paris

Thromboangiitis obliterans

Not yet recruiting

Study on Botulinum Toxin Type A for Treating Buerger's Disease in Patients Eligible for Injection Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Anti-myelin-associated glycoprotein associated polyneuropathy

Not yet recruiting

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Systemic lupus erythematosus

Not recruiting

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:UCB Biopharma

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Dermatitis atopic

Not recruiting

A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Axial spondyloarthritis+2

Not recruiting

A study testing SPY072 compared to placebo in adults with moderately to severely active rheumatologic disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Spyre Therapeutics Inc.

Anti-neutrophil cytoplasmic antibody positive vasculitis

Not recruiting

A Study of Tarperprumig Safety and Effectiveness in Adults with Blood Vessel Inflammation Caused by ANCA Antibodies

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Alexion Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.